Lori Laffel1. 1. Pediatric, Adolescent and Young Adult and Genetics and Epidemiology Sections, Joslin Diabetes Center , Harvard Medical School, Boston, Massachusetts.
Abstract
OBJECTIVE: This study was designed to evaluate accuracy, performance, and safety of the Dexcom (San Diego, CA) G4(®) Platinum continuous glucose monitoring (CGM) system (G4P) compared with the Dexcom G4 Platinum with Software 505 algorithm (SW505) when used as adjunctive management to blood glucose (BG) monitoring over a 7-day period in youth, 2-17 years of age, with diabetes. RESEARCH DESIGN AND METHODS: Youth wore either one or two sensors placed on the abdomen or upper buttocks for 7 days, calibrating the device twice daily with a uniform BG meter. Participants had one in-clinic session on Day 1, 4, or 7, during which fingerstick BG measurements (self-monitoring of blood glucose [SMBG]) were obtained every 30 ± 5 min for comparison with CGM, and in youth 6-17 years of age, reference YSI glucose measurements were obtained from arterialized venous blood collected every 15 ± 5 min for comparison with CGM. The sensor was removed by the participant/family after 7 days. RESULTS: In comparison of 2,922 temporally paired points of CGM with the reference YSI measurement for G4P and 2,262 paired points for SW505, the mean absolute relative difference (MARD) was 17% for G4P versus 10% for SW505 (P < 0.0001). In comparison of 16,318 temporally paired points of CGM with SMBG for G4P and 4,264 paired points for SW505, MARD was 15% for G4P versus 13% for SW505 (P < 0.0001). Similarly, error grid analyses indicated superior performance with SW505 compared with G4P in comparison of CGM with YSI and CGM with SMBG results, with greater percentages of SW505 results falling within error grid Zone A or the combined Zones A plus B. There were no serious adverse events or device-related serious adverse events for either the G4P or the SW505, and there was no sensor breakoff. CONCLUSIONS: The updated algorithm offers substantial improvements in accuracy and performance in pediatric patients with diabetes. Use of CGM with improved performance has potential to increase glucose time in range and improve glycemic outcomes for youth.
OBJECTIVE: This study was designed to evaluate accuracy, performance, and safety of the Dexcom (San Diego, CA) G4(®) Platinum continuous glucose monitoring (CGM) system (G4P) compared with the Dexcom G4 Platinum with Software 505 algorithm (SW505) when used as adjunctive management to blood glucose (BG) monitoring over a 7-day period in youth, 2-17 years of age, with diabetes. RESEARCH DESIGN AND METHODS: Youth wore either one or two sensors placed on the abdomen or upper buttocks for 7 days, calibrating the device twice daily with a uniform BG meter. Participants had one in-clinic session on Day 1, 4, or 7, during which fingerstick BG measurements (self-monitoring of blood glucose [SMBG]) were obtained every 30 ± 5 min for comparison with CGM, and in youth 6-17 years of age, reference YSI glucose measurements were obtained from arterialized venous blood collected every 15 ± 5 min for comparison with CGM. The sensor was removed by the participant/family after 7 days. RESULTS: In comparison of 2,922 temporally paired points of CGM with the reference YSI measurement for G4P and 2,262 paired points for SW505, the mean absolute relative difference (MARD) was 17% for G4P versus 10% for SW505 (P < 0.0001). In comparison of 16,318 temporally paired points of CGM with SMBG for G4P and 4,264 paired points for SW505, MARD was 15% for G4P versus 13% for SW505 (P < 0.0001). Similarly, error grid analyses indicated superior performance with SW505 compared with G4P in comparison of CGM with YSI and CGM with SMBG results, with greater percentages of SW505 results falling within error grid Zone A or the combined Zones A plus B. There were no serious adverse events or device-related serious adverse events for either the G4P or the SW505, and there was no sensor breakoff. CONCLUSIONS: The updated algorithm offers substantial improvements in accuracy and performance in pediatric patients with diabetes. Use of CGM with improved performance has potential to increase glucose time in range and improve glycemic outcomes for youth.
Authors: Bruce Buckingham; Roy W Beck; William V Tamborlane; Dongyuan Xing; Craig Kollman; Rosanna Fiallo-Scharer; Nelly Mauras; Katrina J Ruedy; Michael Tansey; Stuart A Weinzimer; Tim Wysocki Journal: J Pediatr Date: 2007-08-24 Impact factor: 4.406
Authors: Dongyuan Xing; Craig Kollman; Roy W Beck; William V Tamborlane; Lori Laffel; Bruce A Buckingham; Darrell M Wilson; Stuart Weinzimer; Rosanna Fiallo-Scharer; Katrina J Ruedy Journal: Diabetes Technol Ther Date: 2011-02-07 Impact factor: 6.118
Authors: Robert H Slover; John B Welsh; Amy Criego; Stuart A Weinzimer; Steven M Willi; Michael A Wood; William V Tamborlane Journal: Pediatr Diabetes Date: 2011-07-03 Impact factor: 4.866
Authors: Eva Tsalikian; Larry Fox; Stuart Weinzimer; Bruce Buckingham; Neil H White; Roy Beck; Craig Kollman; Dongyuan Xing; Katrina Ruedy Journal: Pediatr Diabetes Date: 2011-12-13 Impact factor: 4.866
Authors: Richard M Bergenstal; William V Tamborlane; Andrew Ahmann; John B Buse; George Dailey; Stephen N Davis; Carol Joyce; Bruce A Perkins; John B Welsh; Steven M Willi; Michael A Wood Journal: Diabetes Care Date: 2011-09-20 Impact factor: 17.152
Authors: Oliver Schnell; Katharine Barnard; Richard Bergenstal; Emanuele Bosi; Satish Garg; Bruno Guerci; Thomas Haak; Irl B Hirsch; Linong Ji; Shashank R Joshi; Maarten Kamp; Lori Laffel; Chantal Mathieu; William H Polonsky; Frank Snoek; Philip Home Journal: Diabetes Technol Ther Date: 2017-05-22 Impact factor: 6.118